Conversely, “TP53/PPM1D” group had more often a history of gynecological cancer (54%, P = 0.002), more treatment lines (mean 2.79, SD [2.22], P = 0.05), more MDS (54%, P < 0.0001) and more complex karyotypes (84%, P < 0.0001). Here, TP53 is linked to myelodysplastic syndrome.